GABA and the antimalarial drug artemether, which acts on GABAergic pathways, can drive pancreatic cells with an a-cell phenotype toward a b-cell-like phenotype. As reported in two papers (BenOthman et al. and Li et al.) , these drugs can stimulate the production of sufficient numbers of new b-like cells to reverse severe diabetes in mice.
While diabetes continues to grow as a worldwide major health problem, its cause is deceptively simple: b-cell failure. In type 1 diabetes (T1D), b cells are efficiently destroyed by autoimmunity, while in type 2 diabetes (T2D), there is failure of b cells to compensate insulin resistance (Weir and Bonner-Weir, 2013) . We know that providing more b cells with pancreas or islet transplants can normalize blood glucose levels in T1D, and pancreas transplants work well even with T2D. Because control of glucose levels will prevent the devastating complications of diabetes, a major research focus has been on b cell replacement therapy. In principle, this can be accomplished either by transplantation of b cells or by regeneration of the deficient b cells in the pancreas. While impressive research advances are being made with transplantation of b cells derived from embryonic stem cells and induced pluripotent stem (iPS) cells (Millman et al., 2016; Pagliuca et al., 2014; Rezania et al., 2014) , this issue of Cell contains two complementary papers (Ben-Othman et al., 2016; Li et al., 2016 ) that provide a surprising boost to the possibility that b cell regeneration could become a therapeutic option.
It was found that treatment of rodents with GABA (Gamma-AminoButyric Acid) could convert glucagon-producing cells to large numbers of b-like cells seen both as increased islet size and number. Importantly, this dramatic regeneration could reverse severe diabetes induced by the b cell toxin streptozocin. The path toward this striking result came from earlier experiments delineating the transcriptional control of b and a cell identity.
In particular, the expression of Pax4 and Arx determine whether developing islet cells end up as b cells or a cells. The importance of Pax4 for determining b cell identity was shown when it was ectopically expressed in embryonic glucagon-expressing cells, which led to their development into b-like cells (Collombat et al., 2009) . Moreover, when Pax4 was misexpressed in adult mouse a cells, a-like cells were then seen in the duct epithelium, which is thought to represent neogenesis; remarkably, these cells then turned into b-like cells that could reverse chemically induced diabetes (Al-Hasani et al., 2013) . A complementary result was found when downregulation of Arx in a cells also led to the appearance of a b cell phenotype .
The connection between GABA and b cell expansion would not seem to be obvious, but knowing that this neurotransmitter is made by b cells provided a hint (Sorenson et al., 1991) . Another clue was the provocative study by Soltani et al. (2011) , which showed that GABA treatment led to improved glucose levels in NOD mice, an autoimmune model of diabetes and to regeneration of b cells and reversal of diabetes in a multiple low-dose streptozocin mouse model of diabetes. The current study by Ben-Othman et al. (2016) further strengthened the case for GABA by finding that many genes with increased differential expression in islets from pancreases of mice with overexpression of Pax4 were related to GABA signaling pathways.
The GABA connection is further fleshed out in a complementary study by Li et al. (2016) . They created a mouse b-cell line (Min6) with inducible overexpression of ARX and looked for drugs that would oppose ARX function, thus pushing these cells toward a b cell phenotype as determined by measuring insulin secretion. Hit compounds were then tested to determine if they could induce insulin expression in the murine a cell line a-TC1. This led to the identification of the antimalarial drugs artemisinins, which included artemether and the structural analogs arteether and artesunate. Pull-down experiments showed that artesunate interacted with protein gephyrin ( Figure 1A ), and then, it was found that knocking down gephyrin could inhibit the increase in insulin induced by artemether.
So what does gephyrin do? Its physical interaction with the GABA A receptor complex in a cells seems especially important. GABA, contained in b cells, has been found to inhibit glucagon secretion; it has been postulated that both stimulated insulin and GABA secretion from b cells during meals can reduce glucagon secretion from neighboring a cells (Franklin and Wollheim, 2004) . Thus, GABA acting on GABA A receptors can inhibit glucagon secretion, while artemether, through its binding to gephyrin, can exert similar effects by activating the GABA A receptor complex.
The similar actions of GABA and artemether on a-TC1 cells suggested that shared mechanisms are involved in their effects on the induction of insulin expression and the loss of a cell identity. There are two other pieces of the puzzle. The first is that inhibition of glucagon secretion may also tilt a cells toward a b cell phenotype. Using a cell-permeable inhibitor of proprotein convertase 2 to prevent the conversion of proglucagon to glucagon, a-TC1 cells were found to have increased expression of the transcription factor PAX4 and could be stained for insulin protein. The second provocative finding, in primary human b cells, was that GABA A receptor signaling following artemether treatment led to translocation of ARX from the nucleus to the cytoplasm.
A key unanswered question is: What is the stimulus for the observed massive neogenesis ( Figure 1B) ? An impressive increase of b cell mass through GABA signaling was found in both studies: in one using GABA itself; in the other, artemether. Lineage tracing showed that these new b cells originated from cells that had an a cell identity as defined by activation of glucagon-driven Cre. The magnitude of b cell generation was particularly impressive in that severe diabetes induced by streptozocin could be reversed with GABA treatment. From the study by Ben-Othman et al. (2016) , it was clear that there was a major increase in the number and size of islets even when non-diabetic mice were treated with GABA and that these islets consisted mostly of b-cells. Because most of these newly generated b-like cells developed from glucagon-expressing cells, there are two pathways that could be responsible. First, the existing a cells in islets could be the source of these new b-like cells, but it does not seem that this small population of cells could account the generation of so many b-like cells. The neogenesis pathway seems quantitatively far more important. The duct epithelium was activated as evidenced by epithelium to mesenchymal transition (EMT) markers, followed by the appearance of glucagon-containing cells adjacent to ducts, and then the conversion of these cells as shown by lineage tracing to proliferating b-like cells that formed new islets. While the neogenesis from the duct epithelium seems to be the major pathway for generating new b-like cells, the responsible mechanisms remain an important mystery.
These two studies provide a major advance by showing that stimulation of GABA pathways can reverse the diabetic state in mice by stimulating b cell regeneration. Moreover, these studies provide evidence for similar mechanisms being operative in human islet cells. These striking findings demand that work be done to understand the mechanisms responsible these changes and to determine the therapeutic potential of GABA pathways to restore the b cell mass that is deficient in diabetes. To call it a ''revolution'' might be cliché . In the short span of a decade, research aimed at determining the biological role of DNA repeats called CRISPRs (clusters of interspaced short palindromic repeats) has gone from scientific obscurity to mainstream celebrity. CRISPR repeats are common in bacterial and archaeal genomes, and Barrangou et al. (2007) showed that CRISPRs are part of an adaptive immune system that protects bacteria from viral infection. The discovery of an adaptive immune system in bacteria united a group of scientists around the common goal of understanding the molecular mechanisms of these immune systems-a line of work that quickly led to an unexpected ''revolution'' in genome editing technologies that may cure genetic diseases.
Bacteria and archaea acquire immunity by integrating short fragments of foreign (e.g., viral) DNA into CRISPR loci in their own genome. CRISPR loci provide a molecular memory of previous encounters with foreign DNA, and CRISPR transcripts are processed into short CRISPR RNAs (crRNAs) that guide protective nucleases to foreign targets for cleavage (Figure 1 ). Cas9 is one of these crRNA-guided nucleases, and the discovery that this bacterial protein cleaves both strands of a complementary DNA target led to the creative repurposing of these enzymes as programmable molecular scalpels capable of precise genome surgery in a variety of different cell types and organisms, including humans (Barrangou and Doudna, 2016) . These genome editing technologies are rapidly moving toward clinical applications, and now, two papers-one in the previous issue (Pawluk et al., 2016a) and one in this issue of Cell (Rauch et al., 2017)-independently identify proteins that may improve the safety of these enzymes by functioning like molecular sheaths for the Cas9 scalpel.
Presumably, bacterial immune systems like CRISPRs evolved in response to antagonistic interactions with molecular parasites like phage, where the competing selfish interests of viral replication and host fitness often create a dynamic landscape of selective pressures that drive evolution and genetic innovation. In 1973, the evolutionary biologist Leigh Van Valen famously compared this dynamic evolutionary landscape to Alice's predicament in Lewis Carroll's fantasy novel ''Through the Looking Glass.'' An exasperated Alice complains to the Red Queen that she is exhausted from running, only to find that she is still beneath the same tree under which she had started. Van Valen's metaphor provides a conceptual framework for understanding the constant ''arms race'' between co-evolving species that must perpetually adapt and proliferate-not merely to gain reproductive advantage, but to simply survive (Van Valen, 1973) .
CRISPR-mediated adaptive immune systems represent a formidable barrier to viral predation, and-consistent with the expectations of a biological arms raceviruses have evolved ''anti-CRISPR'' proteins that suppress these immune systems. However, much in the same way that Cas9 wasn't ''discovered'' by scientists looking for a way to precisely edit genomes, anti-CRISPRs were not discovered by scientists looking for a way to suppress CRISPR-mediated immune systems. In 2010, Joe Bondy-Denomy was an
